Trials / Completed
CompletedNCT00002187
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
Detailed description
This is a multicenter, prospective, randomized, open-label study comparing 2 dosage schedules of ISIS 2922.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fomivirsen sodium |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002187. Inclusion in this directory is not an endorsement.